R
Rallybio Corporation (RLYB)
NCM – Real Time Price. Currency in USD
14.03
+0.03 (0.21%)
At close: May 12, 2026, 4:00 PM EDT
13.80
-0.23 (-1.64%)
After-hours: May 12, 2026, 7:46 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
14.03
+0.03 (0.21%)
At close: May 12, 2026, 4:00 PM EDT
13.80
-0.23 (-1.64%)
After-hours: May 12, 2026, 7:46 PM EDT
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
| Name | Position |
|---|---|
| Dr. Martin W. MacKay Ph.D. | Co-Founder & Chairman |
| Dr. Stephen Uden M.D., MBBS | Co-Founder, President, CEO & Director |
| Mr. Jonathan I. Lieber M.B.A. | CFO & Treasurer |
| Date | Type | Document |
|---|---|---|
| 2026-05-05 | RW | d109079drw.htm |
| 2026-05-04 | 8-K | d19625d8k.htm |
| 2026-04-24 | S-4/A | d109079ds4a.htm |
| 2026-03-31 | 8-K | rlyb-20260331.htm |
| 2026-03-17 | S-4 | d109079ds4.htm |
| 2026-03-16 | 10-K | rlyb-20251231.htm |
| 2026-03-02 | 8-K | d108429d8k.htm |
| 2026-03-02 | 425 | d108429d425.htm |
| 2026-01-29 | 8-K | rlyb-20260126.htm |
| 2026-01-02 | DEF 14A | ny20061662x2_def14a.htm |